Effect of 3 Months of Doxazosin Therapy on T-Cell Subsets in Type 2 Diabetic Patients

Abstract

Doxazosin, an α₁-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4⁺, CD8⁺, CD25⁺ and CD69⁺ cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4⁺CD25^+high cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4⁺CD69⁺ and CD8⁺CD69⁺ cells) decreased, whereas that of regulatory T-cells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.

Keywords

Type 2 diabetes Proteinuria Doxazosin Immunomodulation Lymphocytes Regulatory T-cells

References

American Diabetes Association: Standards of medical care in diabetes–2007. Diabetes Care 2007; 30 (suppl 1): S4–S41.

de Zeeuw

Remuzzi

Parving

: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–927.

Jermendy

Ruggenenti

: Preventing microalbuminuria in patients with type 2 diabetes. Diabetes Metab Res Rev 2007; 23: 100–110.

Basi

Fesler

Mimran

: Microalbuminuria in type 2 diabetes and hypertension: A marker, treatment target, or innocent bystander? Diabetes Care 2008; 31 (suppl 2): S194–S201.

Cravedi

Ruggenenti

Remuzzi

: Does remission of renal disease associated with antihypertensive treatment exist? Curr Hypertens Rep 2007; 9: 160–165.

Kuriyama

Otsuka

Iida

: Morning blood pressure predicts hypertensive organ damage in patients with renal diseases: Effects of intensive antihypertensive therapy in patients with diabetic nephropathy. Intern Med 2005; 44: 1239–1246.

Courtney

McCance

Atkinson

: Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003; 52: 1147–1152.

Inukai

Matsutomo

: Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: Effects on glucose and lipid metabolism. J Int Med Res 2004; 32: 206–213.

Derosa

Cicero

D'Angelo

: Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. Cardiovasc Pharmacol 2006; 47: 508–512.

10.

Takahashi

Iwagaki

Tamura

: α1-Adrenergic receptor antagonists induce production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Immunother 2005; 28: 40–43.

11.

Bubien

Cornwell

Bradford

: α1-Adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels. Am J Phys Cell Phys 1998; 275: C702–C710.

12.

Veglio

Tayebati

Schiavone

: α1-Adrenergic receptor subtypes in peripheral blood lymphocytes of essential hypertensives. J Hypertens 2001; 19: 1847–1854.

13.

Brosnan

Sacks

Goldschmidt

: Prazosin treatment during the effector stage of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1986; 137: 3451–3456.

14.

Svec

Vásárhelyi

Pászthy

: Do regulatory T cells contribute to Th1 skewness in obesity? Exp Clin Endocrinol Diabetes 2007; 115: 439–443.

15.

Wykretowicz

Guzik

Wysocki

: Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother 2008; 9: 625–633.

16.

Plećas-Solarović

Hristitć-Zivković

Radojević

: Chronic alpha1-adrenoreceptor blockade produces age-dependent changes in rat thymus structure and thymocyte differentiation. Histol Histopathol 2005; 20: 833–841.

17.

Bao

Huang

Wang

: Expression of α-AR subtypes in T lymphocytes and role of the α-ARs in mediating modulation of T cell function. Neuroimmunomodulation 2007; 14: 344–353.

18.

Elenkov

Wilder

Chrousos

: The sympathetic nerve–an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2000; 52: 595–638.

19.

George

: Mechanisms of disease: The evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2008; 5: 531–540.

20.

Mor

Planer

Luboshits

: Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 893–900.

21.

Gotsman

Grabie

Gupta

: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006; 114: 2047–2055.